加拿大Lorus Therapeutics Inc www.lorusthera.com
是一家在癌症药物科技开发及产品商业化领域的专业生物医药公司
Lorus Therapeutics Inc. is a biopharmaceutical company focused on the discovery, research and development of effective anticancer therapies with high safety profiles. Through its own discovery efforts, as well as acquisition and in-licensing programs, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical to an advanced Phase II clinical trial.
Many of the cancer drugs currently approved for the treatment and management of cancer are toxic with severe side effects. Lorus believes that the future of cancer treatment and management lies in drugs that are effective, have minimal side effects, and improve a patient's quality of life. We also hold the view that no single drug will emerge as a cure for all cancers. Instead, cancer will continue to be treated by many different drugs with a variety of mechanisms of action. Therefore, the Company concentrates on the discovery and the development of different classes of anticancer compounds using several therapeutic approaches to address this multi-mechanistic approach for the treatment of cancer. Each therapeutic approach is dependent on different technologies, which we believe mitigates the development risks associated with a single technology platform. We evaluate the merits of each product throughout the clinical trial process and stringently assess whether commercialization is appropriate.
Lorus has product candidates in three classes of anticancer therapies:
RNA-targeted therapies (antisense and siRNA), based on synthetic segments of DNA or RNA designed to bind to the messenger RNA that is responsible for the production of proteins over-expressed in cancer cells; 
Small molecule therapies based on anti-angiogenic, anti-proliferative and anti-metastatic agents; and 
Immunotherapy, based on biological response modifiers that stimulate anticancer properties of the immune system. 
A strong intellectual property portfolio supports each of the drug candidates in our diverse product pipeline.